Back to results
US 12,616,673 B2Granted
Compounds for use in the treatment of leukemia
AssigneeUniversita' Degli Studi Di Roma “La Sapienza”
InventorsFrancesco Fazi, Silvia Masciarelli
Life of this patent
Estimating the term…
Abstract
The present invention belongs to the field of cancer therapy and relates to a composition or product comprising at least one retinoid compound, at least one arsenic compound and at least one proteasome inhibitor, for use in the treatment of acute myeloid leukemia (AML) where the tumor cells are positive for the FLT3-ITD mutation.
Claims7
A method for treating acute myeloid leukemia in a patient having tumor cells which are FLT3-ITD mutation positive, comprising administering:
- a) all-trans retinoic acid (ATRA) and/or pharmaceutically acceptable salts thereof;
- b) arsenic trioxide (ATO);
- and
- c) a proteasome inhibitor, wherein the proteasome inhibitor is Bortezomib;
- to a patient in need thereof, wherein all-trans retinoic acid (ATRA) is administered at 70 mg/kg, bortezomib is administered at 0.5 mg/kg and arsenic trioxide (ATO) is administered at 3 mg/kg.
2 more elements
Dependencies are inferred from the claim text.